OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW)
<p><em>Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therap...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-08-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | http://oncourology.abvpress.ru/index.php/oncur/article/view/351 |